{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T20:07:56Z","timestamp":1780344476528,"version":"3.54.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.vph.2015.04.004","type":"journal-article","created":{"date-parts":[[2015,6,25]],"date-time":"2015-06-25T09:49:12Z","timestamp":1435225752000},"page":"16-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet\/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and\/or metabolic syndrome"],"prefix":"10.1016","volume":"72","author":[{"given":"Francesca","family":"Santilli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Blardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Scapellato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Guazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Terzuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Tabucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Silvietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Lucani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter Renato","family":"Gioffr\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Scarpini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Dav\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Puccetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2015.04.004_bb0005","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2015.04.004_bb0010","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.23280","article-title":"Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications","volume":"51","author":"Fabbrini","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.vph.2015.04.004_bb0015","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"Chalasani","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vph.2015.04.004_bb0020","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1210\/jc.2007-0482","article-title":"Liver fat in the metabolic syndrome","volume":"92","author":"Kotronen","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.vph.2015.04.004_bb0025","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2015.04.004_bb0030","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1210\/jc.2012-3093","article-title":"Nonalcoholic Fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications","volume":"98","author":"Targher","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.vph.2015.04.004_bb0035","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1001\/archinte.164.19.2169","article-title":"Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults","volume":"164","author":"Kim","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.vph.2015.04.004_bb0040","doi-asserted-by":"crossref","first-page":"R149","DOI":"10.1093\/hmg\/ddh069","article-title":"Genetics of familial combined hyperlipidemia and risk of coronary heart disease","volume":"13","author":"Shoulders","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.vph.2015.04.004_bb0045","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ijcard.2013.01.250","article-title":"Genetic influence in liver steatosis prevalence and proatherothrombotic\/inflammatory profile in familial combined hyperlipoproteinemia","volume":"168","author":"Santilli","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.vph.2015.04.004_bb0050","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2174\/138161208784139701","article-title":"Advanced glycation end products (AGEs) and their involvement in liver disease","volume":"14","author":"Hyogo","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.vph.2015.04.004_bb0055","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2174\/092986709787581888","article-title":"Soluble forms of RAGE in human diseases: clinical and therapeutical implications","volume":"16","author":"Santilli","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.vph.2015.04.004_bb0060","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00109-009-0439-2","article-title":"Receptor for AGE (RAGE) and its ligands \u2014 cast into leading roles in diabetes and the inflammatory response","volume":"87","author":"Yan","year":"2009","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.vph.2015.04.004_bb0065","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/lt.22306","article-title":"What is the role of the receptor for advanced glycation end products\u2013ligand axis in liver injury?","volume":"17","author":"Basta","year":"2011","journal-title":"Liver Transpl."},{"key":"10.1016\/j.vph.2015.04.004_bb0070","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1161\/01.ATV.0000190660.32863.cd","article-title":"Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis","volume":"25","author":"Koyama","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2015.04.004_bb0075","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.2337\/db12-1528","article-title":"sRAGE and risk of diabetes, cardiovascular disease and death","volume":"62","author":"Selvin","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.vph.2015.04.004_bb0080","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.clinbiochem.2009.02.003","article-title":"Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease","volume":"42","author":"Yilmaz","year":"2009","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.vph.2015.04.004_bb0085","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1161\/hq0202.104059","article-title":"Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study","volume":"22","author":"Veerkamp","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2015.04.004_bb0090","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/01.ATV.0000077220.44620.9B","article-title":"Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia","volume":"23","author":"Ayyobi","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5","key":"10.1016\/j.vph.2015.04.004_bb0095","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 Evidence-based guideline for the management of high blood pressure in adults. Report from the Panel Members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2015.04.004_bb0100","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jama.287.3.356","article-title":"Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey","volume":"287","author":"Ford","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2015.04.004_bb0105","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1365-2362.2010.02323.x","article-title":"Assessment of liver stiffness in subjects affected by familial combined hyperlipidaemia with hepatic steatosis","volume":"40","author":"Riggio","year":"2010","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.vph.2015.04.004_bb0110","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.vph.2015.04.004_bb0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.vph.2015.04.004_bb0120","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2010.10.006","article-title":"Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia","volume":"214","author":"Puccetti","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2015.04.004_bb0125","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.freeradbiomed.2010.06.009","article-title":"Determinants of thromboxane biosynthesis in rheumatoid arthritis: role of RAGE and oxidant stress","volume":"49","author":"Ferrante","year":"2010","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.vph.2015.04.004_bb0130","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1373\/clinchem.2008.112243","article-title":"Prediction of recurrent venous thromboembolism by endogenous thrombin potential and d-dimer","volume":"54","author":"Eichinger","year":"2008","journal-title":"Clin. Chem."},{"key":"10.1016\/j.vph.2015.04.004_bb0135","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.clinbiochem.2009.12.021","article-title":"Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions","volume":"43","author":"Riondino","year":"2010","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.vph.2015.04.004_bb0140","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.atherosclerosis.2005.03.012","article-title":"3\u2032UTR\/T polymorphism of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is associated with modified anti-platelet activity of atorvastatin in hypercholesterolemic subjects","volume":"183","author":"Puccetti","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2015.04.004_bb0145","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1161\/01.CIR.0000074207.85796.36","article-title":"Genetic variation in lectin-like oxidized low-density lipoprotein receptor 1 (LOX1) gene and the risk of coronary artery disease","volume":"107","author":"Chen","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2015.04.004_bb0150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2362.2007.01891.x","article-title":"Genetic influence in antithrombotic actions of atorvastatin in hypercholesterolaemia","volume":"38","author":"Puccetti","year":"2008","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.vph.2015.04.004_bb0155","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijcard.2005.09.001","article-title":"Cytokines in acute coronary syndromes","volume":"105","author":"Pasqui","year":"2005","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.vph.2015.04.004_bb0160","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s10238-006-0092-9","article-title":"Pro-inflammatory\/anti-inflammatory cytokine imbalance in acute coronary syndromes","volume":"6","author":"Pasqui","year":"2006","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.vph.2015.04.004_bb0165","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/03014460903393857","article-title":"Population differences in allele frequencies at the OLR1 locus may suggest geographic disparities in cardiovascular risk events","volume":"37","author":"Predazzi","year":"2010","journal-title":"Ann. Hum. Biol."},{"key":"10.1016\/j.vph.2015.04.004_bb0170","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1365-2370.2002.00303.x","article-title":"Allele frequencies of polymorphisms of TNFA, IL-6, IL-10 and IFNG in an Italian Caucasian population","volume":"29","author":"Poli","year":"2002","journal-title":"Eur. J. Immunogenet."},{"key":"10.1016\/j.vph.2015.04.004_bb0175","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/1753944710371483","article-title":"Adiponectin gene polymorphisms and their effect on the risk of myocardial infarction and type 2 diabetes: an association study in an Italian population","volume":"4","author":"Chiodini","year":"2010","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"10.1016\/j.vph.2015.04.004_bb0180","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosis.2010.02.026","article-title":"Genetic involvement in statins induced myopathy. Preliminary data from an observational case\u2013control study","volume":"211","author":"Puccetti","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2015.04.004_bb0185","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/eurheartj\/ehr453","article-title":"Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?","volume":"33","author":"Bhatia","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2015.04.004_bb0190","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jhep.2011.07.028","article-title":"Endogenous formation of N\u03b5-(carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis","volume":"56","author":"Gaens","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.vph.2015.04.004_bb0195","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jhep.2013.11.033","article-title":"Dietary glycotoxins exacerbate progression of experimental fatty liver disease","volume":"60","author":"Leung","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.vph.2015.04.004_bb0200","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vph.2015.04.004_bb0205","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/ars.2010.3719","article-title":"What is the significance of soluble and endogenous secretory receptor for advanced glycation end products in liver steatosis in obese prepubertal children?","volume":"14","author":"D'Adamo","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.vph.2015.04.004_bb0210","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1210\/jc.2013-2936","article-title":"Lower serum endogenous secretory receptor for advanced glycation end product level as a risk factor of metabolic syndrome among Japanese adult men: a 2-year longitudinal study","volume":"99","author":"Momma","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.vph.2015.04.004_bb0215","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/cvr\/cvp036","article-title":"RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice","volume":"82","author":"Sun","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.vph.2015.04.004_bb0220","first-page":"1130","article-title":"Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products","volume":"2011","author":"Feng","year":"1812","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.vph.2015.04.004_bb0225","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.freeradbiomed.2007.06.017","article-title":"Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins","volume":"43","author":"Santilli","year":"2007","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.vph.2015.04.004_bb0230","first-page":"483135","article-title":"Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists?","author":"Ahmed","year":"2012","journal-title":"J. Obes."},{"key":"10.1016\/j.vph.2015.04.004_bb0235","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1210\/jc.2011-2430","article-title":"Intrahepatic insulin exposure, intrahepatocellular lipid and regional body fat in nonalcoholic fatty liver disease","volume":"97","author":"Mehta","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.vph.2015.04.004_bb0240","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/01.CIR.0000081777.17879.85","article-title":"Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case\u2013control comparison from the National Heart, Lung, and Blood Institute Family Heart Study","volume":"108","author":"Hopkins","year":"2003","journal-title":"Circulation"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189115000737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189115000737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T12:55:28Z","timestamp":1537534528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189115000737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":48,"alternative-id":["S1537189115000737"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2015.04.004","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet\/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and\/or metabolic syndrome","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2015.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2015.06.011","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}